Inmunosupresión e infección en el paciente trasplantado

Martorell, 2004, Inmunología del rechazo en el trasplante, 74 Biron, 1997, Activation and function of natural killer cell responses during viral infections, Curr Opin Immunol, 9, 24, 10.1016/S0952-7915(97)80155-0 Marsh, 2005, Nomenclature for Factors of the HLA System, 2004, Hum Immunol, 66, 571, 10.1016/j.humimm.2005.02.002 Auchincloss H, 1996, Antigen processing and presentation in transplantation, Curr Opin Immunol, 8, 681, 10.1016/S0952-7915(96)80086-0 Baid, 2001, Managing the highly sensitized transplant recipient and B cell tolerance, Curr Opin Immunol, 13, 577, 10.1016/S0952-7915(00)00262-4 Young, 1997, Killer cell inhibitory receptor interactions with HLA class I molecules: Implications for alloreactivity and transplantation, Hum Immunol, 52, 1, 10.1016/S0198-8859(96)00258-3 Dallman, 1993, Cytokines as mediators of organ graft rejection and tolerance, Curr Opin Immunol, 5, 788, 10.1016/0952-7915(93)90138-I Chen, 1996, Prevention of Th1 response is critical for tolerance, Transplantation, 61, 1076, 10.1097/00007890-199604150-00016 Waldman, 1996, Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells, Am J Pathol, 148, 105 Sayegh, 1995, CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2, J Exp Med, 181, 1869, 10.1084/jem.181.5.1869 Mottram, 1997, Interleukin (IL) 4, the cytokine that isn’t there: Reactivity of IL-4 antibodies with cells in IL-4 -/- mice, Transplantation, 63, 911, 10.1097/00007890-199703270-00022 Qian, 1996, Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice, Transplantation, 62, 1709, 10.1097/00007890-199612270-00002 Poston, 1999, Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method, Transplantation, 68, 825, 10.1097/00007890-199909270-00015 DeVries, 2003, The role of chemokines and chemokine receptors in alloantigen-independent and alloantigen-dependent transplantation injury, Semin Immunol, 15, 33, 10.1016/S1044-5323(02)00126-4 Horuk, 2001, CCR1-specific non-peptide antagonist: Efficacy in a rabbit allograft rejection model, Immunol Lett, 76, 193, 10.1016/S0165-2478(01)00172-9 Dickenmann, 2002, Why do kidney grafts fail? A long-term single-center experience, Transpl Int, 15, 508, 10.1111/j.1432-2277.2002.tb00207.x Stoves, 2002, Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: A case-control study, Transplantation, 74, 1794, 10.1097/00007890-200212270-00027 Kirk, 2006, Induction immunosuppression, Transplantation, 82, 593, 10.1097/01.tp.0000234905.56926.7f Whiting, 1997, Infectious complications after OKT3 induction in liver transplantation, Liver Transpl Surg, 3, 563, 10.1002/lt.500030602 Sgro, 1995, Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review, Toxicology, %20, 23, 10.1016/0300-483X(95)03123-W Mourad, 2001, Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression, Transplantation, 72, 1050, 10.1097/00007890-200109270-00012 Charpentier, 2003, A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients, Transplantation, 75, 844, 10.1097/01.TP.0000056635.59888.EF Morris, 2006, Alemtuzumab (Campath-1H): a systematic review in organ transplantation, Transplantation, 81, 1361, 10.1097/01.tp.0000219235.97036.9c Barth, 2006, Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation, Transpl Int, 19, 885, 10.1111/j.1432-2277.2006.00388.x Malek, 2006, Campath-1H induction and the incidence of infectious complications in adult renal transplantation, Transplantation, 81, 17, 10.1097/01.tp.0000189713.14993.db Watson, 2005, Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years, Am J Transplant, 5, 1347, 10.1111/j.1600-6143.2005.00822.x Nath, 2005, Fungal infections in transplant recipients receiving alemtuzumab, Transplant Proc, 37, 934, 10.1016/j.transproceed.2005.01.054 Boillot, 2005, Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study, Liver Transpl, 11, 1, 10.1002/lt.20307 Webster, 2004, Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials, Transplantation, 77, 166, 10.1097/01.TP.0000109643.32659.C4 Hershberger, 2005, Daclizumab to prevent rejection after cardiac transplantation, N Engl J Med, 352, 2705, 10.1056/NEJMoa032953 Vincenti, 2005, Costimulation blockade with belatacept in renal transplantation, N Engl J Med, 353, 770, 10.1056/NEJMoa050085 Webster, 2005, Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients, Cochrane Database Syst Rev, 19, 10.1002/14651858.CD003961.pub2 Singh, 2005, Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens, Curr Opin Infect Dis, 18, 342, 10.1097/01.qco.0000172698.52408.be Mathew, 1998, A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, Transplantation, 65, 1450, 10.1097/00007890-199806150-00007 Bernabeu-Wittel, 2002, Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression, Eur J Clin Microbiol Infect Dis, 21, 73, 10.1007/s10096-001-0684-y Paterson, 1998, Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil, Transplantation, 66, 593, 10.1097/00007890-199809150-00007 Chen, 2004, Does mycophenolate mofetil increase the incidence of infections in stable renal transplant recipients initially treated with a two-drug regimen?, Transplant Proc, 36, 2122, 10.1016/j.transproceed.2004.08.015 Troppmann, 2003, Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study, Transplantation, 76, 426, 10.1097/01.TP.0000072016.13090.4E Morales, 2005, Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients, Transplant Proc, 37, 693, 10.1016/j.transproceed.2005.01.045 Webster, 2006, Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials, Transplantation, 81, 1234, 10.1097/01.tp.0000219703.39149.85 Fishman, 1998, Infection in organ-transplant recipients, N Engl J Med, 338, 1741, 10.1056/NEJM199806113382407 Rubin, 1981, Infection in the renal transplant recipient, Am J Med, 70, 405, 10.1016/0002-9343(81)90780-4 Patel, 1997, Infections in Solid-Organ Transplant Recipients, Clin Microbiol Rev, 10, 86, 10.1128/CMR.10.1.86 Singh, 2001, Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients, Clin Infect Dis, 32, 742, 10.1086/319225 Humar, 2006, Am J Transplant, 6, 262, 10.1111/j.1600-6143.2005.01207.x Preiksaitis, 2001, Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients, Clin Infect Dis, 33, S38, 10.1086/320903 2004, Guidelines for the prevention and management of infectious complications of solid organ transplantation, Am J Transplant, 4, 66 Singh, 1996, Human herpesvirus-6 in transplantation: An emerging pathogen, Ann Intern Medical, 124, 1065, 10.7326/0003-4819-124-12-199606150-00007 Berenguer, 2000, HCVrelated fibrosis progression following orthotopic liver transplantation: Increase in recent years, J Hepatol, 32, 673, 10.1016/S0168-8278(00)80231-7 Hirsch, 2003, Lancet Infect Dis, 3, 611, 10.1016/S1473-3099(03)00770-9 Miro, 2004, Trasplante hepático en pacientes con infección por el VIH. Una realidad en 2004, Enferm Infecc Microbiol Clin, 22, 529, 10.1157/13067621 Aguado, 1997, Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA, Transplantation, 63, 1278, 10.1097/00007890-199705150-00015 2004, Guidelines for the prevention and management of infectious complications of solid organ transplantation, Am J Transplant, 4, 110 Singh, 2000, Invasive mycoses in organ transplant recipients: Controversies in prophylaxis and management, J Antimicrob Chemother, 45, 749, 10.1093/jac/45.6.749 Muñoz, 2003, Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients, Clin Infect Dis, 36, 932, 10.1086/368209 2004, Parasitic infection, Am J Transplant, 4, 142 Fischer, 2006, Infections complicating solid organ transplantation, Surg Clin North Am, 86, 1127, 10.1016/j.suc.2006.06.005